Literature DB >> 1969013

Effect of heparin, aspirin, or alteplase in reduction of myocardial ischaemia in refractory unstable angina.

G G Neri Serneri1, G F Gensini, L Poggesi, F Trotta, P A Modesti, M Boddi, A Ieri, M Margheri, G C Casolo, M Bini.   

Abstract

399 out of 474 inpatients with unstable angina were monitored for 48 h and 97 of these were found to be refractory to conventional antianginal treatments and entered a randomised double-blind study. With the initial protocol heparin infusion or bolus were compared with aspirin; with a modified protocol, heparin infusion, the best of these three treatments, was compared with alteplase. Patients were monitored for 3 days after starting treatment and then observed clinically for 4 more days. On the first days of treatment heparin infusion significantly decreased the frequency of angina (by 84-94%), episodes of silent ischaemia (by 71-77%), and the overall duration of ischaemia (by 81-86%). Heparin bolus and aspirin were not effective. Alteplase caused small (non-significant) reductions on the first day only. Only minor bleeding complications occurred.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1969013     DOI: 10.1016/0140-6736(90)90407-v

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  16 in total

Review 1.  Recent advances in the management of unstable angina and non-Q-wave myocardial infarction.

Authors:  R P Steeds; K S Channer
Journal:  Br J Clin Pharmacol       Date:  1998-10       Impact factor: 4.335

Review 2.  Recognition and treatment of unstable angina.

Authors:  C Brunelli; P Spallarossa; P Rossettin; S Caponnetto
Journal:  Drugs       Date:  1996-08       Impact factor: 9.546

Review 3.  Risk factors, interventions and therapeutic agents in the prevention of atherosclerosis-related ischaemic diseases.

Authors:  M Verstraete
Journal:  Drugs       Date:  1991       Impact factor: 9.546

4.  Current and Future Options for Anticoagulant Therapy in the Acute Management of ACS.

Authors:  Charles V Pollack
Journal:  Curr Treat Options Cardiovasc Med       Date:  2013-02

5.  Thrombotic reactant markers in non-ST segment elevation acute coronary syndromes treated with either enoxaparin (low molecular weight heparin) or unfractionated heparin.

Authors:  E Gurfinkel; E Duronto; C Colorio; G Bozovich; M Cohen; B Mautner
Journal:  J Thromb Thrombolysis       Date:  1999-10       Impact factor: 2.300

6.  Correlation between clinical course and quantitative analysis of the ischemia related artery in patients with unstable angina pectoris, refractory to medical treatment. Results of two randomized trials. The European Cooperative Study Group.

Authors:  M J van den Brand; A van Miltenburg; M J de Boer; L R van der Wieken; P J de Feyter; M L Simoons
Journal:  Int J Card Imaging       Date:  1994-09

7.  The impact of membership in a health maintenance organization on hospital admission rates for acute chest pain.

Authors:  S D Pearson; T H Lee; E Lindsey; T Hawkins; E F Cook; L Goldman
Journal:  Health Serv Res       Date:  1994-04       Impact factor: 3.402

8.  Predictors of risk in patients with unstable angina admitted to a district general hospital.

Authors:  J J Murphy; P A Connell; J R Hampton
Journal:  Br Heart J       Date:  1992-05

Review 9.  Alteplase. A reappraisal of its pharmacology and therapeutic use in vascular disorders other than acute myocardial infarction.

Authors:  A J Wagstaff; J C Gillis; K L Goa
Journal:  Drugs       Date:  1995-08       Impact factor: 9.546

Review 10.  Heparin therapy. Regimens and treatment considerations.

Authors:  T M Hyers
Journal:  Drugs       Date:  1992-11       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.